Peter A. Rowe
Peter A. Rowe
Associate Professor
  • :01752 439052

Department of Nephrology
Peninsula Medical School
United Kingdom

Education

Peter Rowe read medicine at Bristol University Medicla School and undertook postgraduate training in both general internal medicine and nephrology in Nottinngham and Glasgow before going to Plymouth.

 

Biography

Before appointment as a substantive consultant in Plymouth he was a senior registrar at the Western Infirmary in Glasgow and registrar in Nottingham. He have an interest in transplant medicine and all the renal units he trained in had an active transplant program as well as offering the complete range of nephrology and dialysis services. 
  His clinical interests are in all aspects of renal transplant medicine, renal vasculitis and hypertension. Late graft loss is an increasingly important cause of transplant failure as short term graft survival rates have progressively improved and his research interests were centred around the progression of chronic kidney disease and the causes of late renal allograft failure, which have some common aspects of pathophysiology. He has studied the prediction and aetiology of progressive graft dysfunction and his MD thesis reported studies of renal haemodynamics in animals and humans with chronic progressive renal failure.
  He has a complementary interest in information management and has continued to develop computerised information systems and apply them to patient care and to research. He plays an active role in clinical governance and holds several management roles, while continuing clinical practice. He holds specialist accreditation in both Nephrology and General (Internal) Medicine.

  He have been an examiner for the London Royal College of Physicians since 2004 and local host for the PACES examination since 2006.

Research Interest

His clinical interests are in all aspects of renal transplant medicine, renal vasculitis and hypertension. Late graft loss is an increasingly important cause of transplant failure as short term graft survival rates have progressively improved and his research interests were centred around the progression of chronic kidney disease and the causes of late renal allograft failure, which have some common aspects of pathophysiology. He has studied the prediction and aetiology of progressive graft dysfunction and his MD thesis reported studies of renal haemodynamics in animals and humans with chronic progressive renal failure.

Professional Activities:

2007-2009

Chairman Hosptital Medical staff  Committee

2005-2007

Member Medical Executive Committee

2004-2007

Medical Lead for Information, Plymouth Hospitals NHS Trust

2004- Present

Examiner Royal College Physicians (London)

2002-2006

Chair British Transplantation Society Ethics Committee

2001-2003

Clinical Director Renal Services, Plymouth Hospitals NHS Trust

2000-2007

Elected Member Local Negotiating Committee

Societies

1979

British Medical Association

1985

Renal Association

1987

European Renal Association

1989

Scottish Renal Association

1989 - 1995

Royal MedicoChirurgical Society of Glasgow

1989

Royal College of Physicians and Surgeons of Glasgow

1989

British Transplant Society

1996

Plymouth Medical Society

1996

American Society of Nephrology

2000

International Society of Nephrology

2005

Fellow of Royal Society of Medicine

2011

European Society of Organ Transplantation

 

Publications

  1. Cytokine secretion in mixed lymphocyte culture: a prognostic indicator of renal allograft rejection in addition to HLA typing. Cartwright NH, Demaine AG, Hurlock NJ, McGonigle RJ, Rowe PA, Shaw JF Szydlo RM, Kaminski ER. Transplant Immunology 2000; 8: 109-114
  2. Percutaneous endoscopic gastrostomy feeding in haemodialysis outpatients. Sayce H, Rowe PA, McGonigle RJS. J Human Nutrition and Dietetics 2000; 13: 333-341
  3. A study of cytokine gene polymorphisms and protein secretion in renal transplantation. Cartwright NH, Keen LJ, Demaine AG, Hurlock NJ, McGonigle RJ, Rowe PA, Shaw JF, Szydlo RM, Kaminski ER. Transplant Immunology 2001; 8: 109-114
  4. Effect of fluvastatin on acute renal allograft rejection: arandomised multicenter trial.Holdaas H, Jardine AG, Wheeler DC, Brekke IB, Conlon PJ, Fellstrom B, Hammad A, Holme I Isoniemi I, Moore R, Rowe PA, Sweny P, Talbot DA, Wadstrom J, Ostraat O. Kidney International 2001; 60: 1990-1997
  5. Activation of NF-kB and MAP kinase cascades by hypothermic stress in endothelial cells. Roberts JR, Rowe PA, Demaine AG. Cryobiology 2002; 44: 161-169
  6. Effects of Immediate Switch from Cyclosporin Microemulsion to Tacrolimus at First Acute Rejection in Renal Allograft Recipients. Briggs D, Dudley C, Pattison J, Pfeffer P, Salmela K, Rowe P, Tydén G, for the European Tacrolimus Renal Rejection Study Group. Transplantation 2003; 75(12): 2058-206
  7. A retrospective study of the prognostic impact of cytokine secretion in mixed lymphocyte culture on long-term graft function following allogeneic renal transplantation. Vijayan Suresha, B Sean Carey, Steve Shaw, Wai Yee Tse, Nicola Cartwright , Jacob Akoh, Richard McGonigle, Peter Rowe, John Shaw, Edward Kaminski. Transplant International 2005; 18: 1067-1071.0
  8. A 5-year audit of haemodialysis access. Akoh JA, Sinha S, Dutta S, Opaluwa AS, Lawson H, Shaw JF, Walker AJ, Rowe PA, McGonigle RJ. Int J Clin Pract. 2005 Jul;59(7):847-51
  9. Revascularization versus Medical Therapy for Renal Artery Stenosis. The ASTRAL Investigators. N Engl J Med 2009; 361:1953-62.
  10. Generic tacrolimus in renal transplantation: trough blood concentration as a surrogate for drug exposure. Connor A, Prowse A, MacPhee I, Rowe PA. Transplantation. 2012; 93(12)
  11. A single-centre comparison of the clinical outcomes at 6 months of renal transplant recipients administered Adoport® or Prograf® preparations of tacrolimus. Andrew Connor, Andrew Prowse, Paul Newell, Peter A Rowe. Clin Kidney J 2013; 6(1): 21-28
  12. Campath, calcineurin inhibitor reduction and chronic allograft nephropathy (3C) study: background, rationale, and study protocol. Haynes R, Baigent C, Harden P et al on behalf of the The 3C Study Collaborative Group. Transplantation Research 2013; 2: 7-16
  13. Alemtuzumab-based induction treatment versus basiliximab-based induction treatment in kidney transplantation (the 3C Study): a randomised trial.
  14. The 3C Study Collaborative Group.The Lancet, Early Online Publication, 28 July 2014; doi:10.1016/S0140-6736(14)61095-3
  15. A genome-wide association study in renal transplantation. The United Kingdom and Ireland Renal Transplant Consortium and The Wellcome Trust Case Control Consortium 3 New Engl J Med, submitted for publication 2015

 

transplantation-research Journal Flyer